Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups

Hanne-Dorthe Emborg, Palle Valentiner-Branth, Astrid Blicher Schelde, Katrine Finderup Nielsen, Mie Agermose Gram, Ida Rask Moustsen-Helms, Manon Chaine, Ulla Holten Seidelin, Jens Nielsen
doi: https://doi.org/10.1101/2021.05.27.21257583

Article Information

doi 
https://doi.org/10.1101/2021.05.27.21257583
History 
  • June 2, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Hanne-Dorthe Emborg1,*,
  2. Palle Valentiner-Branth1,
  3. Astrid Blicher Schelde1,
  4. Katrine Finderup Nielsen1,
  5. Mie Agermose Gram1,
  6. Ida Rask Moustsen-Helms1,
  7. Manon Chaine2,
  8. Ulla Holten Seidelin2 and
  9. Jens Nielsen1
  1. 1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej 2300 Copenhagen, Denmark
  2. 2Data Integration and Analysis, Statens Serum Institut, 5 Artillerivej 2300 Copenhagen, Denmark
  1. ↵*Corresponding Author Hanne-Dorthe Emborg, Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej 2300 Copenhagen, Denmark. T: +45 3268 3937, email: hde{at}ssi.dk
Back to top
Posted June 02, 2021.
Download PDF
Data/Code
Email
Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups
Hanne-Dorthe Emborg, Palle Valentiner-Branth, Astrid Blicher Schelde, Katrine Finderup Nielsen, Mie Agermose Gram, Ida Rask Moustsen-Helms, Manon Chaine, Ulla Holten Seidelin, Jens Nielsen
medRxiv 2021.05.27.21257583; doi: https://doi.org/10.1101/2021.05.27.21257583
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area